Compliance
in real-world clinical settings for colorectal cancer (CRC) screening1*
Proven accuracy in the pivotal ECLIPSE† trial, with 83% sensitivity and 90% specificity2‡§
- One of the largest studies and first of its kind to validate a blood test that detects CRC3
The future of CRC screening starts now. Go
*Compliance rate for the first 8,000 patients that were prescribed Shield and completed it.1
†The ECLIPSE study (NCT04136002) compared to the sensitivity and specificity of cfDNA - only Shield with findings from subsequent colonoscopy in over 20,000 average-risk patients.1,2
‡Specificity detected for advanced neoplasia defined in ECLIPSE as CRC or advanced adenomas.1,3
§Patients had no prior diagnosis of CRC, inflammatory bowel disease, or family history of genetic risk for CRC (eg, Lynch syndrome).3
References: 1. Data on file. Guardant Health, Inc. 2. Guardant Health press release. December 15, 2022. 3. ECLIPSE trial on ClinicalTrials.gov
